ClinicalTrials.gg
CompletedNCT01730469Updated Aug 3, 2017

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

A Phase 1 interventional study of AT1001 150 mg in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-03.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 26 studies in Fabry Disease by BioMarin Pharmaceutical — 3 open to participants now, 4 under way, 2 of them phase 3. Fabry Disease · BioMarin Pharmaceutical.

Enrollment
5th of 19
32 · median 20
Started
2011
with 6 others
Phase 1
5 of 26
none open now
Registered
13th of 26
by date

Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is one of 7 that started in 2011, is one of 5 in phase 1, and was the 13th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

3 of the 26 studies in Fabry Disease by BioMarin Pharmaceutical are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Fabry Disease by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single dose of 150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects with normal renal function and to subjects with mild, moderate, and severe renal impairment.

Read the detailed description

This will be an open-label, non-randomized, multiple-center, sequential group, safety, tolerability, and PK study of a single dose of AT1001 (migalastat HCl, GR181413A) administered orally as a 150 mg dose in fasted healthy control male and female subjects with normal renal function compared to mild, moderate, and severe renally-impaired subjects (classified by level of creatinine clearance [CLcr] as determined by the Cockcroft-Gault formula).

Screening will occur from Day -28 to Day -2. Subjects will check-in to the clinic on Day -1 and receive a single oral dose of 150 mg AT1001 on Day 1. Subjects will be discharged from the clinic on Day 2 (if stable as determined by the Investigator) and return for daily visits on Day 3 through Day 6 for a safety assessment and PK sampling. Subjects will undergo a follow-up visit on Day 7 (+1) and an end of study visit on Day 10 (+1).

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Pharmacokinetics
  • GR181413
  • Safety
  • AT1001
  • Migalastat hydrochloride
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • males or females aged 18 to 70 years inclusive (subjects with normal renal function, mild or moderate renal impairment), and 18 to 75 years inclusive (subjects with severe renal impairment)
  • 18.0 to 40.0 kilogram (kg)/square meter (m\^2) inclusive
  • females who are non-pregnant, non-lactating, or for >=1 year, surgically sterile for >= 90 days, or agree to use approved methods of
  • males will be sterile or use approved methods of contraception
  • understands and signs form Healthy subjects with normal renal function
  • negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in
  • good health with no medical history, physical examination, vital signs, or 12-lead
  • clinical laboratory tests within the reference range or not clinically significant
  • normal renal function (estimated >90 mL/min) at Screening Subjects with mild, moderate or severe renal impairment
  • negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in or verification of a prescription for a positive test
  • renal impairment (estimated CLcr \<90 mL/min)
  • evidence of stable renal impairment defined as two separate estimated CLcr values within 25%
  • clinical laboratory results consistent with their renal condition or of no clinical significance for the study
  • abnormal laboratory values must not be clinically significant. Anemia secondary to renal disease is acceptable if is ≥9 g/dL and no clinically significant symptoms. Liver enzymes and must be below twice the upper normal level
  • subjects with renal impairment must have stable underlying medical conditions \< 90 days before study start
  • stable medication regimen(s) (no new drug(s) or changed dosage(s) \<30 days before study drug)
  • in good general health, allowing for concurrent illnesses associated with chronic kidney disease

Exclusion criteria

Exclusion Criteria:

All subjects:

  • history of or allergies to any drug, unless approved by the Investigator and reviewed by Sponsor/Medical Monitor
  • participation in a study with receipt of an drug \< 5 half-lives or 30 days (whichever is longer) before Check-in
  • use of alcohol, grapefruit, or caffeine-containing foods or beverages \< 72 hours before Check-in, unless approved by the Investigator and reviewed by the Sponsor/Medical Monitor
  • poor peripheral venous access
  • whole blood donation \< 56 days before dosing or plasma donation \< 14 days before dosing
  • receipt of blood products \< 2 months before Check-in
  • history or presence of any abnormal
  • history of alcoholism or drug addiction \< 1 year before Check-in
  • positive test for antibody, or anti-
  • pregnant or breastfeeding

Healthy subjects with normal renal function:

  • use of any tobacco- or nicotine-containing products \< 6 months before Check-in
  • clinically significant (history of or active) cardiac, hepatic, pulmonary, endocrine, neurological, infectious, gastrointestinal, hematologic, oncologic, or psychiatric disease putting the subject at increased risk or could interfere with study objectives
  • screening laboratory values outside normal range and deemed clinically significant by the Investigator
  • use of a prescription drug \< 14 days of dosing or a non-prescription drug \< 7 days before dosing or need of concomitant medication during the study

Subjects with mild, moderate, or severe renal impairment:

  • unstable disease (concurrent medical conditions that have changed significantly \< 90 days)
  • changes in concomitant prescription medications \< 30 days before dosing or expected changes during study
  • use of new non-prescription medication \< 30 days before dosing
  • renal transplant
  • acute or chronic non-renal condition limiting the subject's ability to complete and/or participate in the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    AT1001 150 mg

    Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast

    Drug: AT1001 150 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events to assess safety and tolerability

    Adverse events will be evaluated from Day 1 to the end of study (Day 10 +1).

    Time frame: Day 1 to Day 10 (+1)

  2. Clinical laboratory test values to assess safety and tolerability

    Clinical laboratory evaluations (hematology, clinical chemistry, urinalysis, Hepatitis A and HIV screen) will be evaluated from screening to the end of the study.

    Time frame: Day -28 to Day 10 (+1)

  3. Vital signs to assess safety and tolerability

    Vital signs (oral temperature, respiratory rate, and seated blood pressure) will be performed from screening to the end of the study.

    Time frame: Day -28 to Day 10 (+1)

  4. Physician examination to assess safety and tolerability

    Physical examination (general appearance, skin, thorax/lungs, cardiovascular and abdomen) will be performed from screening to the end of the study.

    Time frame: Day -28 to Day 10 (+1)

  5. Measure of ECG to assess safety and tolerability

    Electrocardiogram (ECG) measures the electrical activity of the heart and the hearts' rhythm. All subjects will undergo ECG testing.

    Time frame: Day -28 to Day 10 (+1)

Secondary outcomes

  1. Maximum observed concentration (Cmax) of AT1001

    Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the resultant maximum plasma concentration (Cmax) will be measured in subjects with impaired renal function and normal renal function.

    Time frame: Day 1 to Day 6

  2. Time to achieve maximum concentration (Tmax) of AT1001

    Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and time to maximum concentration (tmax) will be measured in subjects with impaired renal function and normal renal function.

    Time frame: Day 1 to Day 6

  3. Apparent terminal elimination half life (t1/2 ) of AT1001

    Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and and apparent terminal elimination half-life (t1/2) will be measured in subjects with impaired renal function and normal renal function.

    Time frame: Day 1 to Day 6

  4. Area under the concentration-time curve from time zero to the last measurable concentration (AUC 0-t ) of AT1001

    Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and AUC 0-t will be measured in subjects with impaired renal function and normal renal function

    Time frame: Day 1 to Day 6

  5. Area under the concentration-time curve extrapolated to infinity (AUC 0-inf) of AT1001

    Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and AUC 0-inf will be measured in subjects with impaired renal function and normal renal function

    Time frame: Day 1 to Day 6

  6. Apparent terminal elimination rate constant for AT1001

    Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the apparent terminal elimination rate constant will be measured in subjects with impaired renal function and normal renal function

    Time frame: Day 1 to Day 6

  7. Oral clearance of AT1001

    Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the oral clearance will be measured in subjects with impaired renal function and normal renal function

    Time frame: Day 1 to Day 6

  8. Oral volume of distribution of AT1001

    Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the oral volume of distribution will be measured in subjects with impaired renal function and normal renal function

    Time frame: Day 1 to Day 6

07

Study locations

4 sites
  • GSK Investigational Site
    Costa Mesa, California 92626, United States
  • GSK Investigational Site
    Miami, Florida 33014, United States
  • GSK Investigational Site
    Miami, Florida 33169, United States
  • GSK Investigational Site
    Orlando, Florida 32809, United States
08

References and documents

Publications

  • Johnson FK, Mudd PN Jr, DiMino T, Vosk J, Sitaraman S, Boudes P, France N, Barlow C. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function. Clin Pharmacol Drug Dev. 2015 Jul;4(4):256-61. doi: 10.1002/cpdd.149. Epub 2014 Dec 22. PubMed 27136905 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2012
First posted
Nov 21, 2012
Start
Aug 2011
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Last update
Aug 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01730469
Responsible party
Sponsor
First posted
Nov 21, 2012
Start date
Aug 2011
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Aug 3, 2017

Study contacts

Medical Monitor, Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Larazotide acetate

Start the discussion